NEW TARGETS
Until very recently, the understanding and availability of drug targets in Alzheimer’s has been sparse and concentrated on acetylcholinesterase, NMDA receptors or insoluble amyloid plaque. Cognition Therapeutics has taken a new approach, using the new concept that soluble Abeta oligomers are the primary neurotoxic element causing neuronal degeneration and cognitive decline in Alzheimer’s disease and discovered a brand new drug target, the sigma-2/PGRMC1 receptor.
Learn More
NEW DRUGS
The therapeutic standards of care for Alzheimer’s only treat the cognitive symptoms, do not modify disease progression and at best they are only modestly active, gradually losing their efficacy as the disease becomes more severe. Cognition Therapeutics has applied its innovative drug discovery platform and discovered first in-class small molecule inhibitors of Abeta oligomer binding to neurons that have the potential to modify disease progression in Alzheimer’s disease.
Learn More
NEW HOPE
Very recent clinical advances using Abeta monoclonal antibodies that interact with both soluble Abeta oligomers and insoluble fibrillar ABeta, have demonstrated a reduction in Abeta burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Abeta approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.
Learn MoreLatest News
Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™
PITTSBURGH, February 21, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and
Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
— Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement — Pittsburgh, Feb. 19, 2019 — Cognition Therapeutics, Inc., a clinical
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
Drs. Kaj Blennow, John Harrison and Henrik Zetterberg Join Medical Advisory Board Pittsburgh, Nov. 27, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection
Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
PITTSBURGH, Nov 8, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today